Project Grant R43HL174237
Award Date
5/1/24
Completion Date
10/31/25
Dollars Obligated
$549K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Poquonock Bridge, CT 06340, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this 17-month grant, with an end date of February 28, 2025, is to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. Novomedix has developed a series of small molecule compounds that inhibit...
This $286,739 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Fibronox, L.L.C., a woman-owned small business. The project aims to assess the clinical translatability of inhaled Nrf2 activator therapy for idiopathic pulmonary fibrosis (IPF), a devastating age-related fibrotic disease with limited treatment options. Specifically, the work will evaluate the efficacy of three FDA-approved...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,748 to Mechanobiologix LLC to develop a stiffness-based drug discovery platform for idiopathic pulmonary fibrosis (IPF). The key products and services to be delivered include: Integrating micro- and macro-scale stiffness measurements in human precision-cut lung slices (HPCLS) with traditional IPF research endpoints to...
This is a Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The primary grant recipient is the Sanford Burnham Prebys Medical Discovery Institute (SBP), located in La Jolla, CA. The goal of this R61/R33 phased grant is to further characterize and optimize novel small molecule inhibitors that selectively target the YAP/TAZ transcription co-factors in lung fibroblasts, with the aim of...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The total funding amount is $356,250.00, awarded on September 15, 2024, with a planned completion date of February 28, 2025. The project is being conducted by Vasarya Therapeutics, Inc., a for-profit, woman-owned...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the assessment of a peptide-based therapy for treating lung fibrosis, a common and serious condition associated with systemic sclerosis. The $389,754 award to Thendor Therapeutics LLC will fund in vivo studies evaluating the therapeutic potential of the peptide in a murine model of lung fibrosis....
This Project Grant award, valued at $1,909,362, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The goal of the funded project is to perform a side-by-side evaluation of the top three most promising NOX4 inhibitor drug candidates for the treatment of pulmonary fibrosis, with a focus on validating selectivity, assessing mode of action, and determining the therapeutic index and maximum tolerated...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina (MUSC) from August 2024 to June 2026. The funding supports research to develop peptide-based therapies for the treatment of pulmonary fibrosis, a serious and fatal lung disease. Specifically, the project aims to simultaneously test identified anti-fibrotic peptides in...
This Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The $1,410,668 award to The Methodist Hospital Research Institute (HMRI) in Houston, Texas, will span the period from January 1, 2025 to November 30, 2028. The key objectives are to elucidate the molecular mechanisms by which CDK9...